Scalp cooling to prevent chemotherapy-induced alopecia<sup>,</sup>

Silva, Giselle de Barros; Ciccolini, Kathryn; Donati, Aline; Hurk, Corina van den

doi:10.1016/j.abd.2020.03.005

Acessibilidade / Reportar erro

Brasil

Anais Brasileiros de Dermatologia

Español English

Brasil

Español English

sumário « anterior atual seguinte »

Sumário

Review • An. Bras. Dermatol. 95 (5) • Sep-Oct 2020 • https://doi.org/10.1016/j.abd.2020.03.005 copy

Scalp cooling to prevent chemotherapy-induced alopecia^☆ ☆ How to cite this article: Silva GB, Ciccolini K, Donati A, Hurk C. Scalp cooling to prevent chemotherapy-induced alopecia. An Bras Dermatol. 2020;95:631–7. ^,^☆☆ ☆☆ Study conducted at the Hospital Alemão Oswaldo Cruz, São Paulo, SP, Brazil.

Authorship SCIMAGO INSTITUTIONS RANKINGS

Abstract

Chemotherapy-induced alopecia causes an important impact on cancer patients and its risk of persistence is currently a considerable issue in cancer survivors. Of the various interventions proposed for the prevention of chemotherapy-induced alopecia, scalp cooling has emerged as an effective and safe strategy. This paper aims to provide an overview on scalp cooling and chemotherapy-induced alopecia prevention.

KEYWORDS
Alopecia; Antineoplastic combined chemotherapy protocols; Cooling; Drug therapy; Prevention and mitigation

Studied in animal models	Studied in human trials: not effective	Studied in human trials: effective
Anti-doxorubicin²⁹29 Balsari AL, Morelli D, Ménard S, Veronesi U, Colnaghi MI. Protection against doxorubicin-induced alopecia in rats by liposome-entrapped monoclonal antibodies. FASEB J. 1994;8:226-30.	Topical minoxidil²³23 Duvic M, Lemak NA, Valero V, Hymes SR, Farmer KL, Hortobagyi GN, et al. A randomized trial of minoxidil in chemotherapy-induced alopecia. J Am Acad Dermatol. 1996;35:74-8.	AS101^a a More evidence needed. ³⁰30 Sredni B, Xu RH, Albeck M, Gafter U, Gal R, Shani A, et al. The protective role of the immunomodulator AS101 against chemotherapy-induced alopecia studies on human and animal models. Int J Cancer. 1996;65:97-103.
Topical epinephrine and norepinephrine³¹31 Soref CM, Fahl WE. A new strategy to prevent chemotherapy and radiotherapy-induced alopecia using topically applied vasoconstrictor. Int J Cancer. 2015;136:195-203.	Parathyroid hormone receptor (PPR) ligands³²32 Skrok A, Bednarczuk T, Skwarek A, Popow M, Rudnicka L, Olszewska M. The effect of parathyroid hormones on hair follicle physiology: implications for treatment of chemotherapy-induced alopecia. Ski Pharmacol Physiol. 2015;28:213-25.	Scalp cooling⁹9 Nangia J, Wang T, Osborne C, Niravath P, Otte K, Papish S, et al. Effect of a scalp cooling device on alopecia inwomen undergoing chemotherapy for breast cancer: the SCALP randomized clinical trial. JAMA. 2017;317:596-605.^,³³33 van den Hurk CJ, Peerbooms M, van de Poll-Franse LV, Nortier JW, Coebergh JW, Breed WP. Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients – results of the Dutch Scalp Cooling Registry. Acta Oncol. 2012;51:497-504.^,³⁴34 Rugo HS, Klein P, Melin SA, Hurvitz SA, Melisko ME, Moore A, et al. Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer. JAMA. 2017;317:606-14.
Topical n-acetyl cysteine³⁵35 Jiménez JJ, Huang HS, Yunis AA. Treatment with ImuVert/N-acetylcysteine protects rats from cyclophosphamide/cytarabine-induced alopecia. Cancer Invest. 1992;10:271-6.	Scalp tourniquet³⁶36 Maxwell MB. Scalp tourniquets for chemotherapy-induced alopecia. Am J Nurs. 1980;80:900-3.
Topical antioxidants (resveratrol, aminothiol)³¹31 Soref CM, Fahl WE. A new strategy to prevent chemotherapy and radiotherapy-induced alopecia using topically applied vasoconstrictor. Int J Cancer. 2015;136:195-203.	Topical calcitriol³⁷37 Paus R, Schilli MB, Handjiski B, Menrad A, Henz BM, Plonka P. Topical calcitriol enhances normal hair regrowth but does not prevent chemotherapy-induced alopecia in mice. Cancer Res. 1996;56:4438-43.
Topical cyclosporine A³⁸38 Hussein A, Stuart A, Peters WP. Protection against chemotherapy-induced alopecia by cyclosporin a in the newborn rat animal model. Dermatology. 1995;190:192-6.	DHL-HisZnNA³⁹39 Sagawa N, Ohno S, Hiratsuka T, Kondo N, Iwata H, Bando H, et al. The utility of DHL-HisZnNa, a novel antioxidant, against anticancer agent-induced alopecia in breast cancer patients: a multicenter phase II clinical trial. Breast Cancer Res Treat. 2019;176:625-30.
Immunomodulators (Il-1,⁴⁰40 Jimenez JJ, Yunis AA. Protection from 1-beta-D-arabinofuranosylcytosine-induced alopecia by epidermal growth factor and fibroblast growth factor in the rat model. Cancer Res. 1992;52:413-5. imuvert⁴¹41 Houssein AM. Chemotherapy-induced alopecia: new developments. South Med J. 1993;86:489-96.)
Acid FGF, EGF⁴⁰40 Jimenez JJ, Yunis AA. Protection from 1-beta-D-arabinofuranosylcytosine-induced alopecia by epidermal growth factor and fibroblast growth factor in the rat model. Cancer Res. 1992;52:413-5.
CDK2 inhibitors⁴²42 Greengard P, Meijer L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002;23:417-25.
Caspase-3 inhibitors⁴³43 Porter AG, Jänicke RU. Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 1999;6:99-104.
Multi-target iron chelator M30⁴⁴44 Lim YC, Kim H, Lim SM, Kim JS. Genetic analysis of a noval antioxidant multi-target iron chelator, M30 protecting against chemotherapy-induced alopecia in mice. BMC Cancer. 2019;19:149.

Sociedade Brasileira de Dermatologia Av. Rio Branco, 39 18. and., 20090-003 Rio de Janeiro RJ, Tel./Fax: +55 21 2253-6747 - Rio de Janeiro - RJ - Brazil
E-mail: revista@sbd.org.br

Acompanhe os números deste periódico no seu leitor de RSS

[1] ⁎ Corresponding author. giselle_barros@yahoo.com.br